The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Abstract
Purpose: In the ASPIRE study of carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide plus dexamethasone (Rd) in patients with relapsed or refractory multiple myeloma, progression-free survival was significantly improved in the carfilzomib group (hazard ratio, 0.69; two-sided P < .001). This prespecified analysis reports final overall survival (OS) data and updated safety results. Patients and Methods: Adults with relapsed multiple myeloma (one to three prior lines of therapy) were eligible and randomly assigned at a one-to-one ratio to receive KRd or Rd in 28-day cycles until withdrawal of consent, disease progression, or occurrence of unacceptable toxicity. After 18 cycles, all patients received Rd only. Progression-free survival was the primary end point; OS was a key secondary end point. OS was compared between treatment arms using a stratified log-rank test. Results: Median OS was 48.3 months (95% CI, 42.4 to 52.8 months) for KRd versus 40.4 months (95% CI, 33.6 to 44.4 months) for Rd (hazard ratio, 0.79; 95% CI, 0.67 to 0.95; one-sided P = .0045). In patients receiving one prior line of therapy, median OS was 11.4 months longer for KRd versus Rd; it was 6.5 months longer for KRd versus Rd among patients receiving ≥ two prior lines of therapy. Rates of treatment discontinuation because of adverse events (AEs) were 19.9% (KRd) and 21.5% (Rd). Grade ≥ 3 AE rates were 87.0% (KRd) and 83.3% (Rd). Selected grade ≥ 3 AEs of interest (grouped terms; KRd v Rd) included acute renal failure (3.8% v 3.3%), cardiac failure (4.3% v 2.1%), ischemic heart disease (3.8% v 2.3%), hypertension (6.4% v 2.3%), hematopoietic thrombocytopenia (20.2% v 14.9%), and peripheral neuropathy (2.8% v 3.1%). Conclusion: KRd demonstrated a statistically significant and clinically meaningful reduction in the risk of death versus Rd, improving survival by 7.9 months. The KRd efficacy advantage is most pronounced at first relapse.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2008) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,240
Palumbo, A., Avet-Loiseau, H., Oliva, S., Lokhorst, H. M., Goldschmidt, H., Rosinol, L., Richardson, P., Caltagirone, S., Lahuerta, J. J., Facon, T., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.2267 · Cited by 2,210
Self-citationDaratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445
Self-citationKumar, S. K., Dispenzieri, A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Pandey, S., Kapoor, P., Dingli, D., Hayman, S. R., Leung, N., et al. (2014) · Leukemia · doi:10.1038/leu.2013.313 · Cited by 1,369
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Self-citationOral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Moreau, P., Masszi, T., Grzasko, N., Bahlis, N. J., Hansson, M., Pour, L., Sandhu, I., Ganly, P., Baker, B. W., Jackson, S. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516282 · Cited by 1,060
Dimopoulos, M. A., Goldschmidt, H., Niesvizky, R., Joshua, D., Chng, W.-J., Oriol, A., Orlowski, R. Z., Ludwig, H., Facon, T., Hajek, R., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30578-8 · Cited by 401
Self-citationClinical Course of Patients With Relapsed Multiple Myeloma
Kumar, S. K., Therneau, T. M., Gertz, M. A., Lacy, M. Q., Dispenzieri, A., Rajkumar, S. V., Fonseca, R., Witzig, T. E., Lust, J. A., Larson, D. R., et al. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.7.867 · Cited by 365
Dimopoulos, M. A., Chen, C., Spencer, A., Niesvizky, R., Attal, M., Stadtmauer, E. A., Petrucci, M. T., Yu, Z., Olesnyckyj, M., Zeldis, J. B., et al. (2009) · Leukemia · doi:10.1038/leu.2009.147 · Cited by 363
Self-citationModelling Survival Data in Medical Research.
D'Agostino, R. B., & Collett, D. (1995) · Journal of the American Statistical Association · doi:10.2307/2291354 · Cited by 223
Dimopoulos, M. A., Lonial, S., White, D. J., Moreau, P., Palumbo, A. P., Miguel, J. F. S., Shpilberg, O., Anderson, K. C., Grosicki, S., Špıčka, I., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14787 · Cited by 148
Self-citationTherapy for Relapsed Multiple Myeloma
Dingli, D., Ailawadhi, S., Bergsagel, P. L., Buadi, F. K., Dispenzieri, A. A., Fonseca, R., Gertz, M. A., Gonsalves, W. I., Hayman, S. R., Kapoor, P., et al. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.01.003 · Cited by 146
Self-citationAvet‐Loiseau, H., Fonseca, R., Siegel, D. S. D., Dimopoulos, M. A., Špıčka, I., Masszi, T., Hájek, R., Rosiñol, L., Goranova-Marinova, V. S., Mihaylov, G. G., et al. (2016) · Blood · doi:10.1182/blood-2016-03-707596 · Cited by 126
Self-citationCornell, R. F., & Kassim, A. A. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.307 · Cited by 103
Song, X., Cong, Z., & Wilson, K. L. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1105202 · Cited by 84
Stewart, A. K., Dimopoulos, M. A., Masszi, T., Špıčka, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S. D., Niesvizky, R., Jakubowiak, A. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.9648 · Cited by 79
Self-citationDimopoulos, M. A., Stewart, A. K., Masszi, T., Špıčka, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S. D., Mihaylov, G. G., Goranova-Marinova, V. S., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14549 · Cited by 73
Self-citationDimopoulos, M. A., Stewart, A. K., Masszi, T., Špıčka, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S. D., Mihaylov, G. G., Goranova‐Marinova, V., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.31 · Cited by 69
Self-citationHow I treat first relapse of myeloma
Harousseau, J. L., & Attal, M. (2017) · Blood · doi:10.1182/blood-2017-03-726703 · Cited by 67
The alpha spending function approach to interim data analyses
DeMets, D. L., & Lan, G. (1995) · Cancer Treatment and Research · doi:10.1007/978-1-4615-2009-2_1 · Cited by 58
Evolution of carfilzomib dose and schedule in patients with multiple myeloma: A historical overview
Jakubowiak, A. J. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.02.005 · Cited by 48
Self-citationManagement of Carfilzomib-Associated Cardiac Adverse Events
Mikhael, J. R. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.01.008 · Cited by 39
Hari, P., Mateos, M., Abonour, R., Knop, S. T., Bensinger, W., Ludwig, H., Song, K., Hájek, R., Moreau, P., Siegel, D. S. D., et al. (2017) · Leukemia · doi:10.1038/leu.2017.122 · Cited by 24
Self-citationJakubowiak, A. J., DeCara, J. M., & Mezzi, K. (2017) · Hematology · doi:10.1080/10245332.2017.1328165 · Cited by 20
Self-citation
Cited by
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.014 · Cited by 900
Self-citationMultiple myeloma: 2022 update on diagnosis, risk stratification, and management
Rajkumar, S. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26590 · Cited by 883
van de Donk, N. W. C. J., Pawlyn, C., & Yong, K. L. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00135-5 · Cited by 869
Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management
Rajkumar, S. V. (2020) · American Journal of Hematology · doi:10.1002/ajh.25791 · Cited by 789
Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534
Metadata
- Authors
- Siegel, D. S., Dimopoulos, M. A., Ludwig, H., Facon, T., Goldschmidt, H., Jakubowiak, A., San-Miguel, J., Obreja, M., Blaedel, J., & Stewart, A. K.
- Venue
- Journal of Clinical Oncology
- Published
- 2018-03-10
- Volume
- 36
- Issue
- 8
- Pages
- 728-734
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2784152305
- Cited by
- 271
- References
- 26
- FWCI
- 24.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.